Addition of metformin to concurrent chemoradiation in patients with locally advanced non–small cell lung cancer: The NRG-LU001 phase 2 randomized clinical trial
Importance Non–small cell lung cancer (NSCLC) has relatively poor outcomes. Metformin
has significant data supporting its use as an antineoplastic agent. Objective To compare
chemoradiation alone vs chemoradiation and metformin in stage III NSCLC. Design, Setting,
and Participants The NRG-LU001 randomized clinical trial was an open-label, phase 2
study conducted from August 24, 2014, to December 15, 2016. Patients without diabetes
who were diagnosed with unresectable stage III NSCLC were stratified by performance …
has significant data supporting its use as an antineoplastic agent. Objective To compare
chemoradiation alone vs chemoradiation and metformin in stage III NSCLC. Design, Setting,
and Participants The NRG-LU001 randomized clinical trial was an open-label, phase 2
study conducted from August 24, 2014, to December 15, 2016. Patients without diabetes
who were diagnosed with unresectable stage III NSCLC were stratified by performance …